SERENDIP
VECTOR OF SUCCESS
THANKS TO
A modular plant-based non-viral vector
and a licensing business model,
OUR MISSION FOR OUR PARTNERS,
Designing, developing and producing
more performant therapeutic assets
starting with oncology applications
Our partners
Serendip focuses on partnering with developers of biological molecules (proteins, peptides, RNA) who aim to turn them into drug products.
We collaborate with academic research teams, whether fundamental, translational, or clinical, as well as with private development teams, such as biotech and biopharma companies.
Their problems
The most common technical challenges that can affect the future safety and efficacy of a drug product are well known and vary depending on the type of molecule modality, from proteins to RNA, and the targeted cells.
Conventional vectors (Lipid Nanoparticles, Viral Vectors or even conjugated antibodies) are typically used to deliver the active therapeutic agent, but they often remain sub-optimal.
For instance, in addition to cell-targeting and payload limiations, the active molecule may degrade rapidly after injection, trigger a non-desired immune response, exhibit toxicity, or suffer from issues related to production or preservation.
In addition to technical challenges, the economic viability of a drug development program is often at risk and can lead to its termination. That’s why development and manufacturing costs need to be optimized, ideally starting from the molecule’s design phase.
Our added-value
- Whether a partner is already facing a technical hurdle at a non-regulatory preclinical stage that requires a change in molecule modality,
- Or aims to proactively mitigate technical risks or economic viability from the early design phase of a new molecule,
- Or seeks to improve a marketed product or a molecule already tested in clinical phases,Serendip leverages a modular vectorization technology and a quality-by-design approach to provide a real added value in managing the technical risks commonly encountered during drug development.Beyond addressing technical challenges in the biopharma industry, Serendip’s solution aims also to deliver positive societal and environmental impacts. It supports a broad range of medical needs (oncology, infectious diseases, autoimmune diseases, etc.) and leverages a plant-based platform that is environmentally sustainable.
The business model
Serendip positions itself as a key player in the development and production of novel biological molecules, primarily based on proteins, peptides, or RNA.
From the early design phase to the early clinical phases, Serendip offers to tailor, produce and license its platform to meet the specific needs of each partner.
Serendip is fully invested in its partners’ success and is willing to share in the risks and the gains. Its co-development and licensing business model fosters flexibility and enables strong, trust-based collaborations centered around the partner’s molecule and drug development program.
